Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Details Textual)

v2.4.0.8
Summary of Significant Accounting Policies (Details Textual) (USD $)
3 Months Ended 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
Summary Of Significant Accounting Policies [Line Items]        
Research and Development Expense, Total $ 3,699,057 $ 583,524 $ 6,184,762 $ 1,019,950
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3,060,301 3,210,126 3,060,301 3,210,126